###begin article-title 0
Polymorphism of Matrix Metalloproteinase-3 Promoter Gene as a Risk Factor for Coronary Artery Lesions in Kawasaki Disease
###end article-title 0
###begin p 1
###xml 926 927 926 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 966 967 966 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
Kawasaki disease (KD) is a major cause of acquired coronary artery diseases in childhood. The serum levels of matrix metalloproteinase (MMP)-3 and MMP-9 in KD have been reported to be significantly higher than other diseases. Several studies have demonstrated that MMP-3 5A/6A polymorphism and MMP-9 C-1562T polymorphism modify each transcriptional activity in allele specific manner. We hypothesized that these polymorphisms may play a role as a risk factor for development of coronary artery lesions (CAL) in KD. Eighty-three patients, diagnosed with KD in Cheju National University Hospital from January 2000 to February 2004, were divided into two groups according to the presence of CAL. Genotyping of MMP-3 and MMP-9 gene polymorphisms were determined by restriction fragment length polymorphism. With regard to MMP-3 gene polymorphism, the KD with CAL group had a higher frequency of 6A/6A genotype than control group (p=0.0127) and the KD without CAL group (p=0.0036). However, no significant differences in the allele and genotype distributions of the MMP-9 polymorphism were observed. These findings suggest that MMP-3 6A/6A genotype may be an independent risk factor for CAL formation in KD.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 657 658 657 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 887 888 887 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 171 178 <span type="species:ncbi:9606">infants</span>
###xml 189 197 <span type="species:ncbi:9606">children</span>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
Kawasaki disease (KD) is a multi-systemic type of vasculitis including coronary involvement (1). It is an acute, febrile, and exanthematous illness that primarily affects infants and young children characterized by wide spread vascular inflammation of coronary arteries and other medium sized arteries (2). Coronary artery lesions (CAL), coronary artery dilatation or aneurysms, are the most important complications and develop in approximately 15-25% of affected patients with KD (3). Immunological abnormalities during the acute phase of KD are characterized by the activation of immunoregulatory cells and an excess production of inflammatory mediators (4). The activated neutrophils and monocytes, producing a large amount of matrix metalloproteinases (MMPs), migrate into vascular lesions, and newly produced MMPs are thought to be related with coronary artery complications in KD (5).
###end p 3
###begin p 4
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 889 890 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Polymorphisms of MMP-3 and MMP-9 genes have been reported to be associated with disease susceptibility, severity and progression of atherosclerosis and aneurysms (6-9). The polymorphism in the promoter region of MMP-3 gene on chromosome 11q 22 has been identified (6) and it is bi-allelic with one variant containing a run of 6 adenosines (6A) while the other has five (5A). This MMP-3 5A allele has higher transcriptional activity than 6A allele (10). Two types of polymorphisms in the MMP-9 gene on chromosome 20q 12.2-13.1 have been shown to be functionally important (7). These are a (CA)n microsatellites polymorphism at position -90 (11) and a single nucleotide polymorphism at position -1562 of the translation start site. The cytosine to thymidine transition at position -1562 of the MMP-9 gene is associated with approximately 50% greater promoter activity than that of C-allele (9).
###end p 4
###begin p 5
These findings led to us to hypothesize that these polymorphisms, which modify the transcriptional activities of MMPs, could be genetic risk factors for CAL in KD.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
Study population
###end title 7
###begin p 8
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1031 1032 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1087 1088 1087 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1137 1138 1137 1138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 321 326 <span type="species:ncbi:9606">child</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 791 799 <span type="species:ncbi:9606">patients</span>
###xml 973 981 <span type="species:ncbi:9606">children</span>
###xml 1146 1154 <span type="species:ncbi:9606">patients</span>
###xml 1172 1180 <span type="species:ncbi:9606">patients</span>
###xml 1258 1266 <span type="species:ncbi:9606">patients</span>
###xml 1271 1279 <span type="species:ncbi:9606">patients</span>
###xml 1308 1316 <span type="species:ncbi:9606">Patients</span>
###xml 1383 1391 <span type="species:ncbi:9606">patients</span>
###xml 1408 1416 <span type="species:ncbi:9606">patients</span>
One hundred controls with no history of Kawasaki disease (KD), autoimmune disease, or allergic diseases (50 males and 50 females, range 1 to 77 yr olds) were recruited for genotyping of MMP-3 and MMP-9 promoter gene polymorphism. Adult healthy controls were enrolled from subjects attending routine medical check-ups and child controls were admitted for elective surgery or transient acute infection. We retrospectively reviewed the medical records of 121 KD patients at the Cheju National University Hospital, Jeju, Korea, from January 2000 to February 2004. KD was diagnosed according to the criteria proposed by the Japanese Kawasaki Disease Research Committee (12). Echocardiography was obtained within 2 weeks of the onset or before intravenous immunoglobulin administration. Forty-two patients (34.7%) had CALs on echocardiography. The CAL was defined as the criteria proposed by Nakano et al. (13); the largest diameter of coronary artery was greater than 2.5 mm in children with a body surface area (BSA) of less than 0.5 m2, greater than 3 mm in those of BSA between 0.5 and 1 m2 and more than 4 mm in those of BSA more than 1 m2. Among patients diagnosed KD, 83 patients, available for genotyping of MMP gene polymorphism, were enrolled. Of the 83 patients, 34 patients had coronary artery lesion. Patients were divided into two groups according to the presence of CAL: 34 patients with CAL and 49 patients without CAL.
###end p 8
###begin p 9
###xml 304 311 <span type="species:ncbi:9606">patient</span>
The following laboratory data were analyzed for elucidating of its association with the development of CAL: white blood cell (WBC) counts, platelet counts, erythrocyte sedimentation rate (ESR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and C-reactive protein (CRP). Data from the patient's first visit to the hospital were obtained.
###end p 9
###begin p 10
###xml 32 40 <span type="species:ncbi:9606">children</span>
All controls and parents, whose children were involved in this study, gave written consent to participation and genotyping. This study was approved by the Clinical Research Committee in Cheju National University Hospital.
###end p 10
###begin title 11
Genotype analysis
###end title 11
###begin p 12
###xml 310 312 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 314 316 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
Genomic DNA was extracted from the peripheral blood using a genomic DNA purification kit (Wizard(R); Promega, Madison, WI, U.S.A.) according to the provided protocol. Genotyping of MMP-3 and MMP-9 promoter gene polymorphism were determined by restriction fragment length polymorphism, as previously described (14, 15).
###end p 12
###begin title 13
5A/6A polymorphism in the promoter region of MMP-3
###end title 13
###begin p 14
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 429 430 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 442 445 438 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 682 685 678 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xmn</italic>
###xml 783 784 779 780 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 795 798 791 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xmn</italic>
###xml 920 921 916 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 948 951 944 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xmn</italic>
Genotyping of MMP-3 promoter polymorphism was examined with a modification of the method described by Dunleavey et al. (14). In brief, PCR amplification was conducted with the primer (5'-GAT TACAGA CAT GGG TCA CA-3'and 5'-TTT CAA TCA GGA CAA GAC GAA GTT T-3'), annealed to the proximity of the 5A/6A polymorphism. Genomic DNA was amplified in 50 microL of reaction mixture containing 10 pM of each primer, 0.2 mM dNTPs, 2 mM MgCl2, and 2.0 U Taq polymerase (Promega, Madison, WI). The amplification conditions were as follow: 94℃ for 30 sec, 55℃ for 30 sec, and 72℃ for 30 sec, for a total 35 cycles with an extension at 72℃ for 7 min. The resulting 120 bp PCR product was digested Xmn I restriction endonuclease (Promega). The 5A allele, possessing a recognition sequence 5'-GAA (N)4 TTC-3'for Xmn I, cleaved the PCR product to 97 bp and 23 bp fragments. The PCR product deriving from the 6A allele, contains 5'-GAA (N)5 TTC-3'did not digested by Xmn I. Undigested PCR product was sequenced (ABI Prism 377 automatic sequencer) to confirm the 6A allele.
###end p 14
###begin title 15
C-1562T promoter polymorphism of MMP-9
###end title 15
###begin p 16
###xml 218 219 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 231 234 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 447 450 443 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sph</italic>
###xml 636 639 632 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sph</italic>
Genomic DNA were PCR-amplified in a 50 microL reaction mixture containing 10 pM of each primers (5'-GCC TGG CAC ATA GTA GGC CC-3'and 5'-CTT CCT AGC CAG CCG GCA TC-3'), 0.2 mM dNTPs, 100 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, and 2.0 U Taq polymerase (Promega). The amplification conditions were as follow: 95℃ for 1 min, 63℃ for 1 min, and 72℃ for 1 min, for a total 35 cycles with an extension at 72℃ for 5 min. PCR products were digested with 2U of Sph I restriction endonuclease (Promega) over 1 hr at 37℃. The final products were electrophoresed on 2% agarose gel and visualized directly with ethidium-bromide staining. The T allele at Sph I site gives rise to a 435 bp fragment rather than one of 247 bp or 188 bp fragments for C allele.
###end p 16
###begin title 17
Statistical analysis
###end title 17
###begin p 18
###xml 591 592 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The SPSS package (SPSS 10.0 for Windows) was used for statistical analysis. Allele frequencies were deduced from genotype frequencies, and differences in the distribution of genotypes were determined by the chi-square test. In order to analyze the comparison of the frequencies of combined genotype between the KD with CAL group and the KD without CAL group, the chi-square test from 2x4 contingency table was applied. Clinical parameters between the KD with CAL group and the KD without CAL group were expressed as mean+/-standard deviation and were compared by using the Student's t-test. P less than 0.05 were accepted as statistically significant.
###end p 18
###begin title 19
RESULTS
###end title 19
###begin p 20
###xml 63 70 63 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 314 321 314 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 582 589 582 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 788 789 784 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 796 803 792 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 298 305 <span type="species:ncbi:9606">patient</span>
The distributions of the MMP-3 and MMP-9 genotype are shown in Table 1. The observed distributions of the MMP-3 and MMP-9 genotype were in Hardy-Weinberg equilibrium. No significant differences in the distribution of MMP-3 and MMP-9 genotype and allelic frequency were observed between control and patient groups (Table 1). There was no significant difference between the KD with CAL group and KD without CAL group with respect to sex, age at diagnosis, duration of fever, WBC and platelet count, ESR, serum levels of aspartate aminotransferase (AST), and C-reactive protein (CRP) (Table 2). The KD with CAL group demonstrated significantly higher serum levels of alanine aminotransferase (ALT) in acute phase than the KD without CAL group (56.07+/-66.93 IU/L versus 98.43+/-113.41 IU/L, p<0.05, Table 2).
###end p 20
###begin p 21
###xml 277 284 277 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 579 580 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 642 643 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 676 683 676 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 915 922 915 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 1131 1132 1131 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1141 1148 1141 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
We assessed the association of MMP-3 and 9 gene polymorphisms with development of CAL in KD patients. For MMP-9 C-1562T polymorphism, no significant association was observed between control group and the KD with CAL group or the KD without CAL group and the KD with CAL group (Table 3). T allele carriers were more frequently observed in patients without CAL compared with patients with CAD or control group, but these differences were not statistically significant. For MMP-3 gene polymorphism, the KD with CAL group had a higher frequency of 6A/6A genotype than control group (p=0.0127, OR=0.18 (0.03 to 0.84)) and the KD without CAL group p=0.0036, OR=0.13 (0.02 to 0.66), Table 3). For the combination of MMP-3 and MMP-9 gene polymorphism, 4 major combined genotypes in the study groups were 6A/6A C/C, 6A/6A C/T, 6A/5A C/C, and 6A/5A C/T. Combined 6A/5A C/T genotype was not observed in the KD with CAL group (Table 3). The frequency of the 6A/6A C/C genotype was greater in the KD with CAL group than in the KD without CAL group, and the KD with CAL group had less often the 6A/5A C/C genotype than the KD without CAL group (p=0.0169, Table 3).
###end p 21
###begin title 22
DISCUSSION
###end title 22
###begin p 23
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
In KD, CAL appeared within the first 4 weeks of illness, and more than half of CALs were gradually regressed within 1 yr after onset. However, some might be progressed into completely obstructive or markedly stenotic coronary lesions (3). Fujiwara et al. (16) documented four stages in the pathology of the coronary arteries under KD. Acute inflammatory changes are seen in the first 6-9 days in the intima and adventitia, and become panvascular lesions by 12-25 days. Subsequently, aneurysms are seen mostly within the first 2 weeks of the early phase of the disease. During the acute stage, large thrombi are frequently noted, and then marked fibrosis, intimal thickening with recanalization, thrombi, and severe stenosis are seen after 40 days.
###end p 23
###begin p 24
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 980 982 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
###xml 1018 1026 <span type="species:ncbi:9606">patients</span>
###xml 1377 1385 <span type="species:ncbi:9606">patients</span>
MMP-3, an important member of metalloproteinase family, is produced by various types of cells; fibroblasts, smooth muscle cells, and macrophages. MMP-3 potentially contributes to the development of structural alterations in the vessel wall by degradation of extracellular matrix proteins such as proteoglycans, laminin, fibronectin and collagen type III, IV, V and IX (10). MMP-9 is also thought to play an important role in facilitating the extravasation and migration of neutrophils by breaking down the basement membrane (17). Senzaki et al. (5) reported that MMP-9 level in pre-intravenous immunoglobulin (IVIG) therapy and MMP3 level in the post-IVIG therapy were significantly higher in KD patients with CAL than in control group or KD patients without CAL. They also reported that the mean levels of serum MMPs (MMP-2, 3, and 9) were significantly higher in KD patients before IVIG therapy than afebrile control subjects or other febrile disease subjects (18). Cho et al. (19) reported in the study with Korean patients that MMP9 levels were significantly higher before IVIG therapy, and decreased through the convalescent stage. The serum MMP9 levels showed significantly positive correlation with the circulating leukocyte counts. Therefore, we hypothesized that genetic association of MMP activity may play a role as a susceptibility factor for development of CAL in patients with KD.
###end p 24
###begin p 25
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
The MMP-3 5A/6A polymorphism had been analyzed in the association with atherosclerosis and aortic aneurysms. 5A allele, higher promoter activity than 6A allele, was more frequent in patients with abdominal aortic aneurysms, intracranial aneurysms (8) and coronary aneurysms (20). Conversely, 6A allele had been found to be associated with angiographic progression of coronary atherosclerosis (6, 10), restenosis after balloon angioplasty (21) and accelerated growth of coronary atheroma (6). In our study, the KD with CAL group had a higher frequency of 6A/6A genotype than control group or the KD without CAL group. The 6A/6A genotype is a potential susceptibility factor for CAL in our study. This result is paradoxical, given that 6A allele has been associated with lower transcriptional activity and known to insufficient MMP-3 expression (22).
###end p 25
###begin p 26
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
The T allele of C-1562 T MMP-9 polymorphism is associated with approximately 50% greater promoter activity than that of C allele. Jones et al. (23) found that genotypes carrying the T allele of this polymorphism were significantly more common in patients with abdominal aortic aneurysm compared with controls or patients with peripheral vascular disease. They concluded that C-1562T MMP-9 promoter polymorphism is a strong independent risk factor for abdominal aortic aneurysms. In our study, no significant differences in the allele and genotype distributions of the MMP-9 polymorphism were observed. However, T allele carriers were more observed in patients without CAL compared with patients with CAL.
###end p 26
###begin p 27
###xml 325 333 <span type="species:ncbi:9606">patients</span>
For the combination of MMP-3 and MMP-9 gene polymorphism, the frequency of the 6A/6A C/C genotype was greater in the KD with CAL group than in the KD without CAL group, and the KD with CAL group had less often the 6A/5A C/C genotype than the KD without CAL group. The present results might suggest that development of CAL in patients with KD is more dependent on genotypes of MMP-3 than that of MMP-9.
###end p 27
###begin p 28
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 224 231 <span type="species:ncbi:9606">patient</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
###xml 756 764 <span type="species:ncbi:9606">patients</span>
###xml 985 993 <span type="species:ncbi:9606">patients</span>
###xml 1043 1051 <span type="species:ncbi:9606">patients</span>
The serum level of ALT is one of the indices of liver damage and a common test item at the initial examination of patients with KD. The advantage to examine the data obtained at the initial examination is that the ALT in KD patient at the acute stage has not been affected by the salicylate treatment. Uehara et al. (24) reported that the ALT of 50 IU/L or more was noted in 49% of the patients with transient cardiac conditions and 52% of those with persistent cardiac disorders. The elevation of the serum ALT at the initial examination was related to the complications of both transient and persistent cardiac disorders. In our study, the ALT levels in initial examination showed significantly higher in the KD with CAL patients than the KD without CAL patients. However, the changes in ALT level within an individual could not be demonstrated because only the data on the ALT measured at the initial examination were available. Comparing the serum ALT levels for a large number of patients will clarify more effectively the role of ALT in patients with KD.
###end p 28
###begin p 29
###xml 485 486 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
However, the association of the MMP gene polymorphism with CAL in KD does not necessarily imply that the genetic variation is responsible for the increased risk of CAL. The increased levels of MMPs may be related with increased infiltration of MMPs producing cells in the coronary artery. Moreover, the association of MMP gene polymorphism with CAL in KD may arise from racial differences of the study populations. The frequency of MMP-3 6A allele has been reported to 65% in Finnish (8), 55% in French (20) and 85% in Korean (15). In our study, the prevalence of MMP-3 6A allele was 85.5% in controls and 88.6% in KD patients. The prevalence of MMP-9 T allele was reported to 22.9% in North American, 30% in Swedish and 6% in Korean population (25-27). The frequency of this allele was 13.5% in controls and 17.5% in KD patients in this study.
###end p 29
###begin p 30
In conclusion, polymorphism in the MMP promoter gene may be contributed to inter-individual differences of the susceptibility for CAL in KD. This is the first study to evaluate the association of MMP-3 and MMP-9 gene polymorphism with CAL in KD. However, to firmly establish the relationship between MMP-3 and MMP-9 gene polymorphism and CAL in KD, further large-scale studies are required in other populations.
###end p 30
###begin title 31
ACKNOWLEDGEMENTS
###end title 31
###begin p 32
###xml 206 214 <span type="species:ncbi:9606">patients</span>
We thank Ji-Eun Park, Department of Pediatrics, Cheju National University College of Medicine, for the excellent technical assistance. This study would not have been possible without the cooperation of the patients and controls.
###end p 32
###begin p 33
###xml 41 75 41 75 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Seoul National University Hospital</funding-source>
This study was supported in part by 2004 Seoul National University Hospital Pediatrics' Alumni Research Funds.
###end p 33
###begin article-title 34
###xml 117 125 <span type="species:ncbi:9606">children</span>
Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: Clinical observation of 50 cases
###end article-title 34
###begin article-title 35
Acute febrile mucocutaneous lymph node syndrome
###end article-title 35
###begin article-title 36
Fate of coronary aneu-rysms in Kawasaki disease: serial coronary angiography and long-term follow-up study
###end article-title 36
###begin article-title 37
Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions
###end article-title 37
###begin article-title 38
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Circulating matrix metalloproteinase and their inhibitors in patients with Kawasaki disease
###end article-title 38
###begin article-title 39
###xml 41 46 <span type="species:ncbi:9606">human</span>
Preliminary report: genetic variation in human stromelysin gene promoter is associated with progression of atherosclerosis
###end article-title 39
###begin article-title 40
Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1
###end article-title 40
###begin article-title 41
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms
###end article-title 41
###begin article-title 42
Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis
###end article-title 42
###begin article-title 43
###xml 91 96 <span type="species:ncbi:9606">human</span>
Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression
###end article-title 43
###begin article-title 44
Shortened microsatellite d(CA) 21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene
###end article-title 44
###begin article-title 45
Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease
###end article-title 45
###begin article-title 46
Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism
###end article-title 46
###begin article-title 47
The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina
###end article-title 47
###begin article-title 48
Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease
###end article-title 48
###begin article-title 49
###xml 37 42 <span type="species:ncbi:9606">human</span>
Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across the basement membrane
###end article-title 49
###begin article-title 50
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy
###end article-title 50
###begin article-title 51
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Matrix metalloproteinase, tissue inhibitors and cytokines in patients with Kawasaki disease
###end article-title 51
###begin article-title 52
Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease
###end article-title 52
###begin article-title 53
The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis
###end article-title 53
###begin article-title 54
Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases
###end article-title 54
###begin article-title 55
Functional matrix metalloproteinase-9 polymorphism (c-1562T) associated with abdominal aortic aneurysm
###end article-title 55
###begin article-title 56
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Serum alanine aminotransferase concentrations in patients with Kawasaki disease
###end article-title 56
###begin article-title 57
Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis
###end article-title 57
###begin article-title 58
Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis
###end article-title 58
###begin article-title 59
Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention
###end article-title 59
###begin p 60
Distribution of genotypes and alleles of MMP-3 and MMP-9 promoter gene polymorphism
###end p 60
###begin p 61
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 33 39 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*OR=0.76 (95% CI, 0.39 to 1.47), daggerOR=0.388 (95% CI, 0.74 to 2.49). MMP, matrix metalloproteinase; OR, odd ratio; CI, confidence interval.
###end p 61
###begin p 62
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Relation between clinical parameters in KD patients and development of CAL
###end p 62
###begin p 63
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*OR=2.71 (95% CI, 0.85 to 8.95). KD, Kawasaki disease; CAL, coronary artery lesion; WBC, white blood cell; ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein.
###end p 63
###begin p 64
Association of MMP-3 and MMP-9 polymorphism with development of CAL
###end p 64
###begin p 65
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 55 61 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 61 62 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 122 128 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 128 129 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*p=0.0127, OR=0.18 (95% CI, 0.03 to 0.84) vs. control. daggerp=0.0036, OR=0.13 (95% CI, 0.02 to 0.66) vs. KD without CAL. daggerp=0.0169, vs. KD without CAL. KD, Kawasaki disease; CAL, coronary artery lesion; MMP, matrix metalloproteinase.
###end p 65

